Chemo-Induced Peripheral Neuropathy: 2010 Archive

Phase 2A Clinical Study shows Positive Results

December 2010: DARA BioSciences reports additional positive results from its successfully completed study for the treatment of neuropathic pain in patients with cancer.

Learn more about Phase 2A Clinical Study shows Positive Results

Source: GlobeNewswire

13th World Congress on Pain

October 2010: The results of a new study to evaluate the safety and efficacy of an drug to treat neuropathic pain in cancer patients was presented by DARA BioSciences at the annual meeting in Montreal.

Learn more about 13th World Congress on Pain

Source: InsuranceNewsNet.com

Drug Combination Improves Survival in Pancreatic Cancer

August 2010: A combination of older chemotherapeutic drugs have improved the median overall survival of certain patients with pancreatic cancer as reported at the annual meeting of the American Society of Clinical Oncology.

Learn more about Drug Combination Improves Survival in Pancreatic Cancer

Source: Clinical Oncology

Peripheral Neuropathy: managing the side effects of chemotherapy

June 2010: Sheryl Ness, Nurse educator at the Mayo Clinic has published an article outlining the symptoms of chemo induced PN and steps you can take to releive some of the symptoms.

Learn more about Peripheral Neuropathy: managing the side effects of chemotherapy

Source: Mayo Clinic

Paclitaxel Combos Useful as Breast Cancer Adjuvant Therapy

June 2010: Resarchers are finding that combination therapy involving paclitaxel and doxorubicin with or without cyclophophamide is beneficial to acheiving good treatment results. Overall survival rates were 82% wtih a cyclophosphamide regimen and 87% with dose-dense paclitaxel.

Learn more about Paclitaxel Combos Useful as Breast Cancer Adjuvant Therapy

Source: Cure Today

Cabazitaxel: A First in Metastatic Prostate Cancer but Toxicity is ‘Concerning’

June 2010: For the first time, a therapy has shown a survival benefit in men with metastatic prostate cancer after failure on docetaxel-based chemotherapy. This new data was presented at the annual meeting of the American Society of Clinical Oncology.

Learn more about Cabazitaxel: A First in Metastatic Prostate Cancer but Toxicity is ‘Concerning’

Source: Medscape

Send this to a friend